Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Palisade Bio Inc (PALI)

$0.69 -0.06 (-8.46%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	6.88M
Revenue (ttm)	0.00
Net Income (ttm)	-14.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.12

Volume	603,249
Avg Vol	2,641,420
Day's Range	N/A - N/A
Shares Out	9.12M
Stochastic %K	50%
Beta	1.35
Analysts	Strong Sell
Price Target	$8.00

Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement wi...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 704 4900

Website: www.palisadebio.com

Address:

7750 El Camino Real, Suite 2A, Carlsbad, United States

johnnylawrencecobra Aug. 25 at 9:58 PM

$PALI

0 · Reply

Tom678 Aug. 25 at 7:54 PM

$PALI

0 · Reply

Squeezepepper Aug. 25 at 4:03 PM

$PALI News. Excellent interview released today with leading expert in Crohn's Disease and IBD. His kudos to Palisade and PALI-2108 is outstanding based on the track it is on and its potential. https://virtualinvestorco.com/pali/

0 · Reply

juliano777 Aug. 22 at 3:19 PM

$PALI I expect 0,8$ at 0,87$ today

1 · Reply

Stock_Catcher Aug. 22 at 2:16 AM

Fortune Friday Watchlist Pt.19 $WOLF $KAVL $MIRA $PALI $DATS Squeeze Time? 🍋

2 · Reply

franzman74 Aug. 19 at 11:39 AM

$PALI Just pump this fucking title! He lost 1 dollar in 10 days! He presented a 9 million offering!

0 · Reply

TheXten Aug. 19 at 4:39 AM

$PALI agree 👍

0 · Reply

BigBullBigCash Aug. 18 at 1:32 PM

$PALI up 14% in a week...time to take off

0 · Reply

Tom678 Aug. 18 at 12:41 PM

$PALI

0 · Reply

GoLongDontShort Aug. 18 at 11:40 AM

$PALI everybody is chasing the ipo PPCB and nobody is buying this shit

0 · Reply

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Aug 7, 2025, 9:15 AM EDT - 18 days ago

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Jul 31, 2025, 8:45 AM EDT - 25 days ago

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Jul 23, 2025, 8:00 PM EDT - 4 weeks ago

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Jul 22, 2025, 8:45 AM EDT - 4 weeks ago

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 9, 2025, 8:45 AM EDT - 6 weeks ago

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

May 27, 2025, 8:30 AM EDT - 3 months ago

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

May 6, 2025, 8:30 AM EDT - 3 months ago

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

May 1, 2025, 8:30 AM EDT - 4 months ago

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Apr 9, 2025, 8:30 AM EDT - 4 months ago

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Mar 14, 2025, 8:30 AM EDT - 5 months ago

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Mar 12, 2025, 8:30 AM EDT - 5 months ago

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Mar 4, 2025, 8:30 AM EST - 6 months ago

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Feb 20, 2025, 8:45 AM EST - 6 months ago

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Feb 19, 2025, 9:00 AM EST - 6 months ago

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 10, 2025, 8:45 AM EST - 7 months ago

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Jan 29, 2025, 8:45 AM EST - 7 months ago

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Jan 3, 2025, 5:20 PM EST - 8 months ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2024, 8:30 AM EST - 8 months ago

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Dec 13, 2024, 4:05 PM EST - 9 months ago

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 12, 2024, 12:55 PM EST - 9 months ago

What's Going On With Palisade Bio Stock On Thursday?

Dec 12, 2024, 12:05 PM EST - 9 months ago

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 3, 2024, 8:15 AM EST - 9 months ago

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Nov 21, 2024, 8:15 AM EST - 9 months ago

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Nov 12, 2024, 8:45 AM EST - 10 months ago

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Oct 31, 2024, 8:30 AM EDT - 10 months ago

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Oct 10, 2024, 8:30 AM EDT - 11 months ago

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Jul 31, 2024, 9:15 AM EDT - 1 year ago

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Jul 19, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Jul 11, 2024, 8:00 AM EDT - 1 year ago

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Jun 24, 2024, 9:00 AM EDT - 1 year ago

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Jun 21, 2024, 8:15 AM EDT - 1 year ago

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

Jun 11, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

Jun 10, 2024, 9:15 AM EDT - 1 year ago

Palisade Bio to Present at the Virtual Investor Pitch Conference

May 21, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

May 14, 2024, 8:05 AM EDT - 1 year ago

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Appoints Margery Fischbein to its Board of Directors

May 7, 2024, 7:30 AM EDT - 1 year ago

Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

May 2, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

May 1, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Apr 23, 2024, 11:09 AM EDT - 1 year ago

Palisade Bio stock rallies on Strand Life Sciences partnership

Apr 23, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

Apr 16, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool

Apr 11, 2024, 9:15 AM EDT - 1 year ago

Palisade Bio to Participate in the Virtual Investor Lunch Break Event

Apr 10, 2024, 8:15 AM EDT - 1 year ago

Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis™

Apr 3, 2024, 5:30 PM EDT - 1 year ago

Palisade Bio Announces 1-for-15 Reverse Stock Split

Feb 15, 2024, 8:35 AM EST - 1 year ago

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

johnnylawrencecobra Aug. 25 at 9:58 PM

$PALI

0 · Reply

Tom678 Aug. 25 at 7:54 PM

$PALI

0 · Reply

Squeezepepper Aug. 25 at 4:03 PM

0 · Reply

juliano777 Aug. 22 at 3:19 PM

$PALI I expect 0,8$ at 0,87$ today

1 · Reply

Stock_Catcher Aug. 22 at 2:16 AM

Fortune Friday Watchlist Pt.19 $WOLF $KAVL $MIRA $PALI $DATS Squeeze Time? 🍋

2 · Reply

franzman74 Aug. 19 at 11:39 AM

$PALI Just pump this fucking title! He lost 1 dollar in 10 days! He presented a 9 million offering!

0 · Reply

TheXten Aug. 19 at 4:39 AM

$PALI agree 👍

0 · Reply

BigBullBigCash Aug. 18 at 1:32 PM

$PALI up 14% in a week...time to take off

0 · Reply

Tom678 Aug. 18 at 12:41 PM

$PALI

0 · Reply

GoLongDontShort Aug. 18 at 11:40 AM

$PALI everybody is chasing the ipo PPCB and nobody is buying this shit

0 · Reply

juliano777 Aug. 17 at 4:37 PM

$PALI I don't understand how we can issue 9 million new shares without it generating cash for the company? Also, why don't the managers have any shares? How do they expect to encourage new shareholders if they themselves don't show that it's a good time to buy?

1 · Reply

juliano777 Aug. 17 at 1:45 PM

$PALI https://seekingalpha.com/filings/pdf/18703255

0 · Reply

WallStreetBuyDip Aug. 16 at 11:00 AM

I’m especially more strict when it comes to trading Small + Mid caps. Some trade based on momentum or catalyst, I only buy when H% is low, nothing else. Next I’ll trade $PALI + $MMAT I keep a result summary to see if the strategy has been successful or not.

0 · Reply

BigBullBigCash Aug. 15 at 1:41 PM

$PALI 0.85 getting closer the elusive mark

1 · Reply